SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TinfoilHat who wrote (53420)12/11/2019 9:21:25 PM
From: idahoranch16 Recommendations

Recommended By
bobbseytwins2001
CelebrityEquity
erippetoe
Planeteer
RedLeader

and 1 more member

   of 63325
 
He had a few minutes to respond to questions. Being 3rd line and unmet need says without saying that there are at least two lines being used before 132, so of course there are treatments/options in early stage. The 10,000 is probably a good estimate for 3rd line, and since first and second line are now being combined into one treatment, and according to what we heard almost a year ago, the labeling gave us the place behind those two which is really 2nd line in the treatment regimen, third drug.

I liked it and so did everyone I sent it to.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News